Correction to: Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study
Guardado en:
Autores principales: | Sara Bottiroli, Roberto De Icco, Gloria Vaghi, Stefania Pazzi, Elena Guaschino, Marta Allena, Natascia Ghiotto, Daniele Martinelli, Cristina Tassorelli, Grazia Sances |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/db55671cf82a4ebf8f2df0dcd4366182 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany
por: Andreas Straube, et al.
Publicado: (2021) -
Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus
por: Andria Tziakouri, et al.
Publicado: (2021) -
Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study
por: Stewart J Tepper, et al.
Publicado: (2021) -
Acupuncture in migraine prophylaxis in Czech patients: an open-label randomized controlled trial
por: Musil F, et al.
Publicado: (2018) -
Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine
por: C Tassorelli, et al.
Publicado: (2021)